Bone Solutions, Inc. appears in FDA device records as the applicant for premarket notifications covering a magnesium-based bone substitute platform. The supplied filings describe a powder component combined with a mixing solution, and the company's own technology page attributes the material to an acid/base crystallization reaction between magnesium oxide and a phosphate blend. The record set spans several dated clearances, and the most recent entry in the supplied sample is K262230, decided September 11, 2026. The company's public pages list a Colleyville, Texas address and contact details; FDA filing addresses are correspondence addresses and are not treated here as a headquarters. [1][3][6]

Documented products and material composition

The trade names Mg OSTEOREVIVE™ and Mg OSTEOCRETE™ appear together in the K262230 record, which lists the device name as "Mg OSTEOREVIVE™;Mg OSTEOCRETE™" under product code MQV and regulation number 888.3045, with the openFDA device name given as a calcium compound bone void filler in the orthopedic specialty. An earlier clearance, K251522, bundles three trade names — Mg OSTEOINJECT™, Mg OSTEOREVIVE™ and Mg OSTEOCRETE™ — and describes them as a magnesium-based synthetic bone void filler that is moldable, drillable, resorbable, adhesive/cohesive, radiopaque and osteoconductive, supplied as a powder component and a mixing solution. [1][5]

Bone Solutions' own product page describes Mg OSTEOCRETE as a fast-setting magnesium-based bone substitute made from a fully synthetic, pre-measured blend of magnesium, phosphates and a proprietary solution, and states that it remodels into bone over time through creeping substitution. The same page lists a ready-in-30-seconds mixing step and high and medium viscosity variants. The technology page attributes the platform to magnesium and potassium phosphate chemistry derived from magnesium oxide and a phosphate blend. These are company-published descriptions, not independently verified clinical findings. [3][6]

Dated filing trail

The supplied record sample contains one 510(k) entry: K262230, received June 30, 2026 and decided September 11, 2026 with decision code SESE, described as substantially equivalent, traditional clearance type, with a summary and the orthopedic advisory committee. The portfolio snapshot counts one linked record, all on the 510(k) pathway, and the decision counts show one SESE decision; the sample decision counts likewise show one SESE decision for the single sampled record. These are as-of collection counts, not measures of sales, total portfolio or safety performance. [1]

Other numbered sources document earlier clearances for the same product family. K234013, dated December 18, 2023 and received December 19, 2023, covers Mg OSTEOINJECT™, Mg OSTEOREVIVE™ and Mg OSTEOCRETE™ under product codes MQV and OIS. K242372 was cleared October 18, 2024 under product codes MQV, OIS and MBP. K251522, dated October 13, 2025, states that its purpose was to expand indications to include specific language for pediatric patients older than six years. [4][5][7]

Indications as stated in the filings

The K234013 determination describes the device as intended for bony voids or defects of the extremities and pelvis that are not intrinsic to the stability of the bony structure, and notes that such osseous defects may result from benign bone cysts and tumors in adults, may be surgically created, or may result from traumatic injury. The K242372 letter lists an intended use as a bone void filler for the skeletal system, including extremities, pelvis and posterolateral spine, and for use with an intervertebral body fusion device cleared for use with a bone void filler, with indications covering mixing with allograft and autograft. [4][7]

The K251522 letter describes the subject devices as a magnesium-based synthetic bone void filler and identifies the submission as a single 510(k) bundling three separately named devices. The supplied excerpt of that letter does not reproduce the full indication text, so the complete current indications are not restated here. [5]

Identity, identifiers and published contact information

AccessGUDID lists a device record for Mg OSTEOCRETE™ bone graft substitute under identifier B4474415000BSI0, with a customer contact phone number and email address matching those published on the Bone Solutions website. The website lists 5712 Colleyville Blvd., Suite 210, Colleyville, Texas 76034, along with a customer service phone number and email. The K262230 record carries a Colleyville, Texas address and names Drew Diaz as contact. [1][3][8]

The earlier clearance letters route correspondence through PaxMed International, LLC, naming Kevin Thomas as VP and Director of Regulatory Affairs, with addresses in San Diego, California and later Carlsbad, California. Those are regulatory correspondence addresses associated with the applicant's representative, not evidence of a parent company, brand owner or headquarters. No parent, subsidiary or brand relationship is verified in the public documents. [4][5][7]